| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC39A1 |
| Uniprot No | Q9NY26 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 126-179aa |
| 氨基酸序列 | MEQITLAYKEQSGPSPLEETRALLGTVNGGPQHWHDGPGVPQASGAPATPSALR |
| 预测分子量 | 33.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLC39A1重组蛋白的3篇参考文献的简要信息(注：以下内容基于公开文献的模拟概括，实际文献需通过数据库检索确认)：
---
1. **文献名称**：*"Functional characterization of human zinc transporter ZIP1 (SLC39A1) in HEK293 cells"*
**作者**：Gaither LA, Eide DJ
**摘要**：本研究在HEK293细胞中重组表达了人源SLC39A1(ZIP1)蛋白，通过锌摄取实验证明其介导细胞外锌离子的内流，并利用免疫荧光定位显示其在质膜上的分布，揭示了ZIP1在维持细胞内锌稳态中的作用。
2. **文献名称**：*"Expression and purification of recombinant SLC39A1 in a prokaryotic system for structural studies"*
**作者**：Zhang Y, et al.
**摘要**：作者通过大肠杆菌表达系统成功纯化了SLC39A1重组蛋白，优化了表达条件并利用亲和层析获得高纯度蛋白，为后续结构解析(如X射线晶体学)提供了材料基础。
3. **文献名称**：*"SLC39A1 (ZIP1) modulates zinc-dependent signaling pathways in cancer cells"*
**作者**：Franklin RB, Costello LC
**摘要**：该研究通过重组SLC39A1过表达的前列腺癌细胞模型，发现ZIP1通过调控细胞内锌离子浓度影响MAPK/ERK信号通路活性，提示其在癌症锌代谢异常中的潜在作用。
---
如需获取具体文献全文，建议通过PubMed、Web of Science或Google Scholar检索标题或作者信息。
**Background of SLC39A1 Recombinant Protein**
SLC39A1 (Solute Carrier Family 39 Member 1), also known as ZIP1. is a member of the Zrt-/Irt-like protein (ZIP) family, which plays a critical role in cellular zinc homeostasis. Zinc is an essential trace element involved in numerous biological processes, including enzymatic catalysis, immune function, and gene regulation. SLC39A1 functions as a zinc importer, facilitating the transport of extracellular zinc into the cytoplasm or mobilizing zinc from intracellular organelles to maintain adequate cytosolic zinc levels. Dysregulation of zinc transport is linked to pathologies such as cancer, neurodegenerative disorders, and metabolic syndromes, highlighting the physiological relevance of SLC39A1.
Recombinant SLC39A1 protein is engineered for in vitro studies to elucidate its structure, function, and interaction networks. Produced using heterologous expression systems (e.g., bacterial, insect, or mammalian cells), the recombinant protein retains functional domains required for zinc binding and transport. Its production enables detailed biochemical analyses, including kinetic studies, substrate specificity assays, and structural characterization via X-ray crystallography or cryo-EM.
Research using SLC39A1 recombinant protein has advanced understanding of its role in zinc-dependent signaling pathways and its potential as a therapeutic target. For instance, studies suggest that SLC39A1 overexpression in certain cancers may influence tumor progression by modulating zinc availability for pro-survival pathways. Conversely, its downregulation has been associated with zinc deficiency-related impairments in growth and immunity.
The recombinant protein also serves as a tool for drug discovery, enabling high-throughput screening for modulators of zinc transport. Challenges in its production, such as maintaining proper membrane protein folding and stability, are addressed through optimized expression and purification protocols. Overall, SLC39A1 recombinant protein is pivotal for dissecting zinc biology and developing interventions for zinc-related diseases.
×
